



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Surgery*

Manuscript NO: 81549

Title: Immunotherapy in combination with chemotherapy for Peutz-Jeghers syndrome with advanced cervical cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04652425

Position: Peer Reviewer

Academic degree: MD

Professional title: Attending Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2022-11-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-22 14:26

Reviewer performed review: 2022-11-27 12:59

Review time: 4 Days and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

This study reported a case of patients with cervical cancer accompanied by PJS. When the effect of chemotherapy was not good, combined immunotherapy was used to obtain better results, which provided a good reference for the treatment of this kind of disease. Question 1: Why was PD-L1 not tested after the whole exome sequencing to determine the suitability for PD-1 inhibitors more directly? Question 2: The key indicator affecting PD-1 inhibitors is whether the tumor cells express PD-L1 or not. Why put more emphasis on the expression of PD-1 in cervical cancer in the discussion section?



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Surgery*

Manuscript NO: 81549

Title: Immunotherapy in combination with chemotherapy for Peutz-Jeghers syndrome with advanced cervical cancer: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03552327

Position: Peer Reviewer

Academic degree: BSc, DPhil

Professional title: Associate Professor, Associate Research Scientist, Pediatric Gastroenterology Fellow

Reviewer's Country/Territory: Malaysia

Author's Country/Territory: China

Manuscript submission date: 2022-11-22

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2023-01-04 02:40

Reviewer performed review: 2023-01-04 05:27

Review time: 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty



Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation
Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The authors presented a unique case report of a rare disorder, thus no doubt this manuscript would add to the body of knowledge on this subject matter. I would like to propose a revision based on the comments below: 1. Mild language editing required 2. To correct the numbers from figures to being spelled out in lines 75, 84 and 159. 3.All the figures and table lack legends that describe them and key indicators or arrows. 4. Figure 1: What is the H&E on tissue section showing? 5.FINAL DIAGNOSIS Based on the patient's transoral single-balloon enteroscopy findings and the patient's surgical report, we diagnosed her with PJS combined with advanced cervical cancer However, the figure or data is not shown in this paper. I would think this information is crucial as it leads to a final diagnosis. 6.Page 7: Considering that JAK2 can promote PD-1 expression, the patient was treated for the first time with a PD-1 inhibitor (sindilizumab 200 mg, 21 days per cycle) in combination with the CD chemotherapy regimen. JAK2



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

promote PDL-1 in cancer cells (to cite the original reference) 7. OUTCOME AND FOLLOW-UP After two months of follow-up, the patient's vital signs (what exactly?) were stable. The patient also suffered no significant adverse effects and the tumor markers were within the normal ranges (Table?). It would help if the authors elaborate further on the vital signs/ adverse effects and tumor markers and refer to the table. 8. Line 159: 5-fluorouracil - spelling error? 9. Line 188: We performed whole-exome sequencing and identified the relevant causative genes (results not shown and discussed in this paper),